Drugs / 9 Peptides from Her-2/neu, CEA, & CTA
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00892567 | May 2009 → Dec 2011 | breast neoplasm | Craig L Slingluff, Jr | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 9 Peptides from Her-2/neu, CEA, & CTA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00892567 ↗ |
| Modality | Vaccine | “peptide-based vaccine” NCT00892567 ↗ |
| Route | Subcutaneous | “administered subcutaneously” NCT00892567 ↗ |